RealTime Dynamix: Atopic Dermatitis Q1 2017

This Spherix Global Insights report highlights responses from 107 dermatologists surveyed on March 22-23, 2017. Dermatologists provide feedback on the launch of Pfizer’s Eucrisa, attitudes about treatment approaches for biologic agents and familiarity with pipeline agents. Sanofi-Regeneron’s Dupixent was approved on March 28th, making this wave of research a perfect baseline for assessing launch effectiveness.

Click the button below to download highlights from this report.

RTD: Atopic Dermatitis Spotlight

2017-06-18T12:58:42+00:00